Researchers have launched GeneBench-Pro, a rigorous benchmark designed to evaluate artificial intelligence systems on the judgment-heavy, iterative analytical tasks required in computational biology. As genomic sequencing costs continue to plummet, the industry bottleneck has shifted from data acquisition to downstream interpretation. GeneBench-Pro addresses this transition by testing whether models can navigate ambiguity, revise initial hypotheses, select appropriate analytical pathways, and determine when results are ready for clinical or commercial decision-making. The benchmark comprises 129 complex problems spanning genomics, quantitative biology, and translational medicine. Unlike traditional biology benchmarks that rely on historical datasets with arbitrary author-defined solutions, GeneBench-Pro utilizes synthetically generated data with known causal structures. This design enables deterministic grading, prevents information leakage, and ensures that model performance reflects genuine analytical reasoning rather than shortcut exploitation or numerical insensitivity. Each problem is embedded in realistic experimental context, provided with standard bioinformatics tooling, and validated by external domain experts. Ten representative tasks are now open-sourced, with a fifty-question subset slated for independent evaluation by Artificial Analysis. Early evaluation reveals significant strides in frontier AI capabilities. The leading GPT-5.6 Sol model achieved a 28.7 percent pass rate at maximum reasoning depth, rising to 31.5 percent with specialized mode enabled. This represents a dramatic improvement over the original GeneBench, where top-tier models previously scored below five percent. Performance scales strongly with test-time compute, as higher reasoning levels enabled models to solve nearly six times as many questions while consuming roughly two-thirds fewer tokens compared to earlier iterations. GPT-series models consistently outperformed leading open-source alternatives, suggesting a widening gap between proprietary systems and specialized coding-focused open models in high-level scientific reasoning. Despite these advances, substantial limitations remain. Even the strongest models solve fewer than a third of the problems, frequently failing to close the inferential loop and integrate contradictory data into revised strategies. Human specialists typically require twenty to forty hours to complete a single task, whereas AI inference costs mere dollars, highlighting the immediate economic potential of partial automation in target prioritization and hypothesis triage. As biobank-scale datasets continue to expand, benchmarks like GeneBench-Pro will become essential for diagnosing model deficiencies and driving the next generation of reliable scientific AI. The trajectory suggests that as systems close their current reasoning gaps, they could fundamentally accelerate translational medicine and industrial drug discovery.